CQ-0736 / Santolecan Pharmaceuticals - LARVOL DELTA

CQ-0736, a new polysaccharide-based therapeutic modality, targets pan-KRAS tumors with robust antitumor activity via macropinocytosis (AACR 2026) - "CQ-0736 is a polysaccharide-based dual-drug conjugate consisting of a 100 kDa dextran backbone covalently grafted with docetaxel (DTX) and gamma-linolenic acid (GLA)...Remarkably, the direct head to head in vivo comparisons revealed that CQ-0736 significantly outperformed the word class pan-RAS inhibitor RMC-6236 and the marketed KRAS targeted drug Krazati, displaying superior efficacy, longer durability, and much less drug resistance.Mechanistic analyses confirmed that CQ-0736 robustly suppresses proliferation (decreasing PCNA and Ki-67) while driving apoptosis (elevating cleaved PARP), producing superior effects to parent DTX. CQ-0736 represents a highly innovative and clinically promising therapeutic strategy for RAS-driven cancers, a disease with devastating prognosis and few effective options. By turning a fundamental vulnerability of RAS-driven tumors into a drug delivery advantage, CQ-0736 opens a new therapeutic paradigm with the potential to significantly..."

Oncology • KRAS • PCNA